Complete application examination

Created the project successfully.

• Name: Public Sample Examination 11202261196R
• Project ID: project-public-sample
• Biblio source: file (as requested — no application number was linked, so it's not tied to canonical biblio data)
• Status: collecting

Next step per GoVeda's workflow: upload the application's content documents, and label one PF1 or PF37 as the bibliographic document (it doesn't need to parse successfully, just needs to be present). Then the project can be submitted for analysis.

Want me to open the document upload panel for this project now?

Next: Open the project’s document upload panel.

The document upload panel is open. You can drag in a PDF directly, or pick files there — one per doc type, up to 50MB each. Remember to label exactly one document as PF1 or PF37 as the bibliographic source (it doesn't need to parse successfully, just needs to be present) before submitting for analysis.

Next: Upload the application documents, then submit the project for analysis.

The project has been submitted for analysis.

• Status: parsing → analysis will start automatically once parsing completes (summary, prior-art search, LOU, etc.)

Want me to check the processing status now, or wait and check back later?

Next: Check the project’s processing status.

Current stage: parsing — the documents are still being processed.

None of the analysis jobs have started yet:

• Summary: waiting
• Prior Art Search: waiting
• Lack of Unity (LOU) analysis: waiting (blocked on Prior Art Search)

No failures so far. Let me know if you'd like me to check again later.

Next: Recheck processing once analysis is complete.

Analysis is complete — project status is now ready.

• Summary: done
• Prior Art Search: done
• LOU (Lack of Unity) analysis: done

No failures. Everything finished processing. Want me to pull up the summary, prior art results, or the LOU analysis next?

Next: Retrieve the application summary.

The application summary is complete (2 refinement iterations performed). Here's the breakdown:

Core Innovation

Methods to modulate drug–drug interactions between vadadustat (Compound 1, an HIF-PH inhibitor for renal anemia) and co-administered agents, via timing separation and/or dose adjustment, to preserve therapeutic exposure.

Problem Addressed

Patients on vadadustat commonly take other medications (oral iron, calcium/lanthanum phosphate binders, statins, sulfasalazine, furosemide) that alter vadadustat's bioavailability — or vice versa — through chelation, absorption interference, or transporter-mediated effects. No systematic regimen previously existed to control this.

Proposed Solution

Regimen-level strategies — not new chemistry or formulations:

• Timing separation: ≥1 hour or ≥2 hours before/after co-administration (embodiments extend to ~24 hours)
• Dose adjustment: of vadadustat and/or the co-administered drug

Key Clinical PK Data

Dosing: vadadustat tablets at 150 mg/300 mg, daily regimens 150–600 mg. Moderate hepatic impairment (Child-Pugh B) didn't meaningfully alter exposure at a single 450 mg dose.

Independent Claims (12 total)

Cover use of Compound 1 for treating renal anemia while managing co-administration with:

• Multivalent-cation compositions (claims 1, 2) — timing-based bioavailability control
• Statins (claims 11, 12) — dose adjustment (20–80% decrease in embodiments)
• Anti-inflammatories/sulfasalazine (claims 20, 21)
• Diuretics/furosemide (claims 24, 25)
• Hepatic impairment subjects (claim 28)
• BCRP substrates (claims 31, 32)

Want me to pull the prior art recommendations or the LOU analysis next?

Next: Review the recommended prior art.

Here's the recommended prior art (10 hits, all returned — no more pages):

Most likely (X-type candidate):

1. US20190290624A1 — Solid Forms of {[5-(3-Chlorophenyl)-3-Hydroxypyridine-2-Carbonyl]Amino}Acetic Acid, Compositions, and Uses Thereof

Possible: 2. US20180092892A1 — Compositions and Methods for Treating Anemia 3. US20160143891A1 — Compositions and Methods for Treating Anemia 4. US20230285374A1 — Therapeutic Methods Using Vadadustat 5. WO2019042641A1 — Co-Crystal of an Orally Available HIF Prolyl Hydroxylase Inhibitor 6. WO2019030711A1 — Polymorphs and Co-Crystals of Roxadustat 7. JP6173364B2 — A Medicament Containing a Partially Saturated Nitrogen-Containing Heterocyclic Compound as an Active Ingredient 8. US20200095203A1 — Novel Crystalline Forms of {[5-(3-Chlorophenyl)-3-Hydroxypyridine-2-Carbonyl]Amino}Acetic Acid and Processes for Preparation Thereof 9. US5643938A — Pyrazolopyridine Compounds for the Treatment of Anemia 10. US20160256394A1 — Pharmaceutical Dosage Forms Comprising Sodium-1-[6-(Morpholin-4-Yl)Pyrimidin-4-Yl]-4-(1H-1,2,3-Triazol-1-Yl)-1H-Pyrazol-5-Olate

US20230285374A1 (Therapeutic Methods Using Vadadustat, rank 4) is worth a close look given it directly names vadadustat therapeutic methods — likely to overlap on the DDI-timing claims. Want me to pull that one up as a full patent card, or move on to the LOU analysis?

Next: Open the strongest relevant patent.

Here's the strongest candidate — US20190290624A1 ("Solid Forms of {[5-(3-Chlorophenyl)-3-Hydroxypyridine-2-Carbonyl]Amino}Acetic Acid, Compositions, and Uses Thereof"), assigned to Akebia Therapeutics.

Quick relevance notes:

• Same compound family — this patent covers crystalline solid forms of vadadustat itself (Compound I), so it's tightly related on the chemistry side.
• Priority date: 2013-11-15, well ahead of typical DDI-focused filings — could bear on novelty for any claim reciting the compound structurally.
• Status: Active, current claims (33–51) are directed to a crystallization process rather than DDI/dosing regimens — so it's more likely relevant to compound-identity/enablement issues than a direct anticipation of the timing/dose-adjustment claims in this application.
• Family: Part of a large Akebia patent family (78 family members) spanning the vadadustat solid-form portfolio across multiple jurisdictions.

Since its claims focus on crystal form/process rather than DDI management, it's strongest as compound-identity prior art rather than a direct hit on the core DDI-timing claims. Want me to check the LOU analysis next, or look more closely at rank 4 (US20230285374A1, "Therapeutic Methods Using Vadadustat"), which may align more directly with the DDI claims?

Next: Retrieve the Lack of Unity analysis.

LOU verdict: Lack of Unity found (a posteriori) — the application splits into 6 separate inventions.

Why: The shared feature across all claims — "use of Compound 1 for treating renal anemia" — is not novel (disclosed by D2, D3, D4). Since that common feature isn't a special technical feature, each claim group's distinct DDI-management strategy is a separate invention.

Search/examination scope: restricted to Group 1 (claims 1–10, 35, 36) per the generated Section 4 text — divisional applications would be needed to pursue the other 5 groups.

The full Section 4 Written Opinion text (citing D2/D3/D4 with statutory basis under Singapore Patents Act §25(5)(d)) is ready and copyable from the widget above. Want me to pull anything else — e.g., a closer look at D4 (which seemed like your strongest DDI-specific hit) or mark the project completed?

Next: Open the Lack of Unity widget.

The interactive LOU widget is now displayed above — it shows the verdict, all 6 invention groups, the D1–D5 prior-art references linked to their goveda.com pages, and the full Section 4 Written Opinion text with a one-click copy button.

Let me know if you'd like to dig into any specific group further, or move on to something else (e.g., marking the project complete).

Next: Mark the project as completed.

Project "Public Sample Examination 11202261196R" is now marked completed.

• Application: 11202261196R
• Title: Modulation of Drug-Drug Interactions of Vadadustat
• Status: completed

Would you like me to draft a quick retrospective on how this examination went (what worked well, what the tooling could improve) to submit as feedback? Entirely optional — happy to skip it if not needed.